BioCentury | Jun 28, 2019
Preclinical News

June 28 Preclinical Quick Takes: BioNTech targets pancreatitis; plus new targets for HIV and more

...BioNTech could prevent pancreatitis A Science study from Cold Spring Harbor Laboratory suggests the glycan CA19.9 (sialyl Lewis A)...
...disease in a mouse model of CA19.9-driven pancreatitis. CSHL filed a patent application on using anti-CA19.9...
...licensed. In May, BioNTech AG (Mainz, Germany) acquired the license along with MabVax’s Phase I-stage anti-CA19.9...
BioCentury | May 8, 2019
Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

...Inc. (Pink:MBVX) for undisclosed terms. MVT-5873 is a human IgG1 mAb targeting an epitope on CA19.9 (sialyl Lewis A)...
BioCentury | Mar 9, 2018
Clinical News

MabVax reports Phase I data for cancer candidate MVT-1075

...MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) reported interim data from three patients with CA19.9-positive malignancies in the...
...U.S. trial is enrolling about 22 patients with relapsed or refractory pancreatic cancer and other CA19.9-positive...
...CA19.9 coupled to the radioisotope lutetium-177 Indication: Treat relapsed or refractory pancreatic cancer and other CA19.9-positive...
BioCentury | Nov 30, 2017
Clinical News

Berg reports Phase II data for ubidecarenone in metastatic pancreatic cancer

...OS), progression-free survival (PFS), time to progression, tumor response using adaptive molecular responses, change in CA19.9 (sialyl Lewis A)...
...OS), progression-free survival (PFS), time to progression, tumor response using adaptive molecular responses, change in CA19.9 (sialyl Lewis A)...
BioCentury | Nov 17, 2017
Clinical News

Five Prime reports Phase I data for cabiralizumab in pancreatic cancer

Five Prime Therapeutics Inc. (NASDAQ:FPRX) reported preliminary data from a Phase I trial of cabiralizumab (FPA008) in combination with anti-PD-1 mAb Opdivo nivolumab to treat advanced solid tumors and announced upcoming trials sponsored by partner...
BioCentury | Nov 8, 2017
Clinical News

Five Prime regains ground on cabiralizumab update

Five Prime Therapeutics Inc. (NASDAQ:FPRX) added $4.58 (18%) to $30.44 on Wednesday after reporting updated data from a Phase I trial of cabiralizumab (FPA008) in combination with anti-PD-1 mAb Opdivo nivolumab to treat advanced solid...
BioCentury | Nov 2, 2017
Product R&D

Sweet specificity

...Therapeutics Holdings Inc. (NASDAQ:MBVX) is also conducting Phase I trials combining MVT-5873 with MVT-1075, an anti-CA19.9 (sialyl Lewis A)...
...II MabVax Therapeutics Holdings Inc. (NASDAQ:MBVX) 1988 $535.4 MVT-5873 (A) Human IgG1 mAb targeting a CA19.9 (sialyl Lewis A)...
BioCentury | Jul 7, 2017
Clinical News

MabVax begins Phase I of MVT-1075 in CA19.9-positive cancers

...doses of MVT-1075 in about 22 patients with relapsed or refractory pancreatic cancer and other CA19.9-positive...
...are expected by year end. MVT-1075 is a human IgG1 mAb targeting an epitope on CA19.9...
...CA19.9 coupled to the radioisotope lutetium-177 Indication: Treat relapsed or refractory pancreatic cancer and other CA19.9-positive...
BioCentury | Jun 22, 2017
Targets & Mechanisms

Exosomes deliver

Codiak BioSciences Inc. founder Raghu Kalluri has published the first animal data demonstrating exosomes can be used as drug delivery vehicles to treat cancer -- not just diagnose it. The findings also mark the unveiling...
BioCentury | Jun 9, 2017
Clinical News

MabVax reports Phase Ia data for MVT-5873 in pancreatic cancer

...disease. After one 28-day cycle of treatment, 40% of patients had a sustained reduction in CA19.9...
...of the trial this year. MVT-5873 is a human IgG1 mAb targeting an epitope on CA19.9...
...Human IgG1 mAb targeting an epitope on CA19.9 Indication: Treat advanced pancreatic cancer and other CA19.9-positive...
Items per page:
1 - 10 of 70